BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2008

View Archived Issues

OBI-1 effective for bleeds in hemophilia A patients

Read More

FDA approves Concerta for ADHD in adults

Read More

Indevus receives FDA approvable letter for Nebido

Read More

Salix initiates phase III rifaximin trials in non-constipation IBS

Read More

Study data reported for panobinostat in hematological cancers

Read More

Snapshots: Vorinostat in hematological malignancies

Read More

Lowering of Alzheimer's dementia risk similar with different NSAID types

Read More

Anika Therapeutics announces commercial availability of Monovisc in Europe

Read More

New treatments for gastrointestinal disorders disclosed in recent patent literature

Read More

FDA approves Aciphex 20 mg for short-term treatment of GERD

Read More

FDA grants orphan drug designation for bupivacaine in postherpetic neuralgia

Read More

Health Canada grants marketing authorization to Basilea's Zeftera for cSSSI

Read More

ALT-1102 signifcantly reduces disease activity in RRMS in phase IIa study

Read More

Myriad Genetics to discontinue development of Flurizan following disappointing phase III results

Read More

Wyeth KK and Takeda launch new formulation of Enbrel for RA in Japan

Read More

Tripep reports preliminary results from phase I/II clinical study of ChronVac-C in HCV

Read More

Recent patents disclose novel agents for psychiatric conditions

Read More

SGX Pharmaceuticals submits IND application to the FDA for SGX-393 in CML

Read More

New anticancer agents imparted in recent patent literature

Read More

Introgen submits BLA to FDA and MAA to EMEA for Advexin in head and neck cancer

Read More

Novartis Pharma initiates phase I study of oral PTH-134 in postmenopausal osteoporosis

Read More

deCode reports positive results from pharmacology study of antiplatelet therapy DG-041

Read More

Novel DPP-IV inhibitor profiled at LG Life Sciences

Read More

Inhaled liposomal ciprofloxacin reduces bacterial infection, improves lung function in CF study

Read More

NanoViricides to initiate animal efficacy studies of EKC-Cide in Japan

Read More

Synthetic Blood International changes name to Oxygen Biotherapeutics

Read More

VioQuest submits 510(k) application to FDA for Xyfid for skin disorders

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 12, 2025.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing